CDA | Evidence Driven
CDA | Evidence Driven

Xtandi for non-metastatic Castration-Resistant Prostate Cancer – Details

Details

Files
Generic Name:
Enzalutamide
Project Status:
Complete
Therapeutic Area:
Non-metastatic castration-resistant prostate cancer (nm-CRPC)
Manufacturer:
Astellas Pharma Canada, Inc.
Brand Name:
Xtandi
Project Line:
Reimbursement Review
Project Number:
PC0149-000
NOC Status at Filing:
Pre NOC
Performance Metric:
Achieved
Strength:
40 mg
Tumour Type:
Genitourinary
Indications:
Non-metastatic castration-resistant prostate cancer
Funding Request:
High risk, non-metastatic castration-resistant prostate cancer
Pre Noc Submission:
Yes
Sponsor:
Astellas Pharma Canada, Inc.
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Enzalutamide (Xtandi) nm-CRPC – pERC Final Recommendation Final Recommendation March 26, 2019 View PDF
Enzalutamide (Xtandi) nm-CRPC – Final Clinical Guidance Report Guidance Reports March 26, 2019 View PDF
Enzalutamide (Xtandi) nm-CRPC – Final Economic Guidance Report Guidance Reports March 26, 2019 View PDF
Enzalutamide (Xtandi) nm-CRPC – pERC Initial Recommendation Initial Recommendation March 7, 2019 View PDF
Enzalutamide (Xtandi) nm-CRPC – PAG Feedback on Initial Recommendation Feedback March 26, 2019 View PDF
Enzalutamide (Xtandi) nm-CRPC – Submitter Feedback on Initial Recommendation Feedback March 26, 2019 View PDF
Enzalutamide (Xtandi) nm-CRPC – Clinician Feedback on Initial Recommendation Feedback March 26, 2019 View PDF
Enzalutamide (Xtandi) nm-CRPC – Patient COI Declarations COI Declarations March 26, 2019 View PDF
Enzalutamide (Xtandi) nm-CRPC – Clinician COI Declarations COI Declarations March 26, 2019 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : April 10, 2019